The DVL2 Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of A-549 human lung carcinoma cells that have undergone CRISPR/Cas9-mediated disruption of the endogenous DVL2 locus. As polyclonal knockout cells, this population contains a diverse array of gene-inactivating edits, providing a robust loss-of-function model without single?cell cloning. This format is ideal for studying the collective impact of DVL2 deficiency on Wnt signaling dynamics and downstream cellular phenotypes in a physiologically relevant epithelial cancer background.
The parental A-549 cell line is an adherent epithelial line originally derived from explanted lung adenocarcinoma tissue. Widely employed as a model for lung cancer, A-549 cells recapitulate key features of adenocarcinoma, including oncogenic KRAS mutations and aberrant signaling pathways. They are routinely used to investigate epithelial barrier function, tumor cell proliferation, migration, invasion, and response to chemotherapeutic agents, making them a versatile platform for target validation and drug discovery.
DVL2 (Dishevelled Segment Polarity Protein 2) is a central scaffold protein that integrates signals from both canonical and non?canonical Wnt pathways. Upon Wnt ligand engagement with Frizzled receptors and LRP5/6 coreceptors, DVL2 becomes phosphorylated by CK1 and GSK3??, leading to inactivation of the ???catenin destruction complex composed of AXIN1, APC, and GSK3??. This stabilizes ???catenin, which translocates to the nucleus and associates with TCF/LEF transcription factors to drive expression of Wnt target genes. Additionally, DVL2 mediates planar cell polarity signaling by activating small GTPases such as RAC1 and RHOA, and regulates JNK?dependent pathways, influencing cytoskeletal organization and cell movement.
In the context of A-549 lung adenocarcinoma cells, DVL2 is a critical node in the Wnt signaling network that contributes to oncogenic phenotypes. Knockout of DVL2 disrupts the transduction cascade downstream of Wnt ligands like WNT3A, impairing ???catenin?dependent transcription and non?canonical outputs. This perturbation enables researchers to dissect the specific contributions of DVL2 to lung cancer cell proliferation, migration, and chemoresistance, and to explore its crosstalk with other pathways such as Hippo signaling. The polyclonal nature of the knockout population ensures that the observed phenotypes reflect the overall loss of DVL2 function rather than clonal artifacts.
These polyclonal DVL2 knockout cells are well?suited for a range of functional assays. Canonical Wnt activity can be assessed by western blotting for ???catenin stabilization or by TOP/FOP luciferase reporter assays. Transcriptional readouts of Wnt target genes (e.g., AXIN2, MYC) can be measured via RT?qPCR. Non?canonical pathway effects can be examined using transwell migration and invasion assays, as well as actin cytoskeleton staining. The model also supports high?content screening and drug sensitivity profiling of Wnt pathway inhibitors in a lung cancer setting. For further technical details and product support, please contact Ascent Research.
